Windtree Therapeutics, Inc. (WINT) is experiencing a surge in its stock price today following the completion of enrollment for its SEISMiC Extension Phase 2b study investigating istaroxime as a treatment for early cardiogenic shock caused by heart failure. This study aims to build upon the encouraging findings from the previous SEISMiC Phase 2 clinical trial, which demonstrated istaroxime’s potential to improve heart function and address low blood pressure in patients experiencing early cardiogenic shock due to heart failure.
Windtree Therapeutics is hopeful that this new study will reinforce the observations from the previous trial, particularly regarding istaroxime’s favorable renal profile and its lack of association with increased cardiac arrhythmias. A key difference between this study and the previous SEISMiC Phase 2 trial is the extended dosing duration. This study will lengthen the dosing period from 24 hours to 60 hours, allowing for a more in-depth assessment of potential benefits. Furthermore, the study will involve two groups of participants, one receiving a constant dose of istaroxime and the other receiving a decreasing dosage, allowing for a comparison of treatment outcomes.
“We look forward to announcing topline results from the SEISMiC Extension Study by the end of the month and plan to present this data at a major medical meeting in the very near future,” stated Steve Simonson, chief medical officer and senior vice president of Windtree. As of this writing, Windtree stock is showing a significant increase of 18.6% at $3.78, according to data from Benzinga Pro.
